Osteoporosis (OP) is a prevalent skeletal disorder characterized by low bone mass and deterioration of bone tissue, leading to increased bone fragility and a heightened risk of fractures, particularly among the elderly. This condition poses a significant global public health challenge, as osteoporotic fractures contribute substantially to morbidity, mortality, and escalating healthcare costs. Conventional treatments, such as calcium and vitamin D supplementation, often face limitations including side effects, suboptimal efficacy, and poor long-term compliance. Consequently, there is a growing impetus to explore innovative therapeutic strategies that can more effectively enhance bone regeneration and repair. Hydroxyapatite (HAp)-based bone-targeting nanosystems have emerged as a promising frontier in regenerative medicine and drug delivery for bone-related disorders, including OP. HAp, a naturally occurring mineral and a principal component of bone tissue, offers several advantages for nanosystem development: exceptional biocompatibility, chemical similarity to native bone mineral, and the capacity for controlled drug delivery to specific bone sites. These nanosystems can be engineered to optimize size, morphology, and surface functionality, enabling improved integration with bone tissue and targeted delivery of therapeutic agents. Recent advances have demonstrated that HAp-based nanosystems can facilitate personalized care, enhance drug efficacy, and reduce systemic side effects by concentrating therapeutic agents at sites of bone degeneration. Functionalization strategies, like polymer coatings, ion doping, and ligand conjugation – have expanded their potential for bone regeneration, targeted therapy, and combination treatments. This review examines the current trends, mechanisms, and future directions of HAp-based nanosystems for OP, highlighting their potential to transform clinical management and improve patient outcomes.
VijayakumarRBüsselbergD.Osteoporosis: an under-recognized public health problem: local and global risk factors and its regional and worldwide prevalence. J Local Glob Health Sci2016; 2016(1): 2.
2.
ZhaoRMengXPanZ, et al. Advancements in nanohydroxyapatite: synthesis, biomedical applications and composite developments. Regen Biomater2025; 12: rbae129.
3.
ChenYWuXLiJ, et al. Bone-targeted nanoparticle drug delivery system: an emerging strategy for bone-related disease. Front Pharmacol2022; 13: 909408.
4.
FarjaminejadSFarjaminejadRGarcia-GodoyF.Nanoparticles in bone regeneration: a narrative review of current advances and future directions in tissue engineering. J Funct Biomater2024; 15(9): 241.
5.
LiaoJLuLChuX, et al. Cell membrane coated nanoparticles: a cutting-edge drug delivery system for anti-osteoporosis therapy. Nanoscale2024; 16: 8236–8255.
6.
HayashiKZhangCTaleb AlashkarAN, et al. Carbonate apatite honeycomb scaffold-based drug delivery system for repairing osteoporotic bone defects. ACS Appl Mater Interfaces2024; 16(35): 45956–45968.
7.
ElghareebMMElshopakeyGEElkhoolyTA, et al. Estradiol and zinc-doped nano hydroxyapatite as therapeutic agents in the prevention of osteoporosis; oxidative stress status, inflammation, bone turnover, bone mineral density, and histological alterations in ovariectomized rats. Front Physiol2022; 13: 989487.
8.
LiLLiHWangQ, et al. Hydroxyapatite nanoparticles promote the development of bone microtissues for accelerated bone regeneration by activating the FAK/Akt pathway. ACS Biomater Sci Eng2024; 10(7): 4463–4479.
9.
WenCXuXZhangY, et al. Bone targeting nanoparticles for the treatment of osteoporosis. Int J Nanomedicine2024; 19: 1363–1383.
10.
ChindamoGSapinoSPeiraE, et al. Bone diseases: current approach and future perspectives in drug delivery systems for bone targeted therapeutics. Nanomaterials2020; 10(5): 875.
11.
RotmanSGrijpmaDRichardsR, et al. Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics. J Control Release2018; 269: 88–99.
12.
ZhangGZhenCYangJ, et al. Recent advances of nanoparticles on bone tissue engineering and bone cells. Nanoscale Adv2024; 6(8): 1957–1973.
13.
ShiSDuanHOuX.Targeted delivery of anti-osteoporosis therapy: bisphosphonate-modified nanosystems and composites. Biomed Pharmacother2024; 175: 116699.
14.
ShiDLiYTianM, et al. Nanomaterials-based drug delivery systems for therapeutic applications in osteoporosis. Adv Biol2025; 9(8): e2400721.
15.
WangY-MShenJ-T.Chitosan-based promising scaffolds for the construction of tailored nanosystems against osteoporosis: current status and future prospects. J Appl Biomater Funct Mater2024; 22: 22808000241266487.
16.
DayanandanAPChoWJKangH, et al. Emerging nano-scale delivery systems for the treatment of osteoporosis. Biomater Res2023; 27(1): 68.
17.
ZhaoRQianHZhuX, et al. Advancing osteoporotic bone regeneration through tailored tea polyphenols functionalized micro-/nano-hydroxyapatite bioceramics. Adv Funct Mater2024; 34(32): 2401566.
18.
ShresthaSLeeSYShresthaD, et al. Micro/nanometer-sized porous structure of zinc phosphate incorporated Ti(HPO4)2 hydrate bioceramic induces osteogenic gene expression and enhances osteoporotic bone regeneration. Chem Eng J2022; 450: 138360.
19.
ZhangWZhangYHaoZ, et al. Synthetic nanoparticles functionalized with cell membrane-mimicking, bone-targeting, and ROS-controlled release agents for osteoporosis treatment. J Control Release2025; 378: 306–319.
20.
LiangWZhouCJinS, et al. An update on the advances in the field of nanostructured drug delivery systems for a variety of orthopedic applications. Drug Deliv2023; 30(1): 2241667.
21.
WuYSunBTangY, et al. Bone targeted nano-drug and nano-delivery. Bone Res2024; 12(1): 51.
22.
KhajuriaDKVasireddiRTrebbinM, et al. Novel therapeutic intervention for osteoporosis prepared with strontium hydroxyapatite and zoledronic acid: in vitro and pharmacodynamic evaluation. Mater Sci Eng C2017; 71: 698–708.
23.
CheLWangYShaD, et al. A biomimetic and bioactive scaffold with intelligently pulsatile teriparatide delivery for local and systemic osteoporosis regeneration. Bioact Mater2023; 19: 75–87.
24.
Kubiak-MihkelsooZKostrzębskaABłaszczyszynA, et al. Ionic doping of hydroxyapatite for bone regeneration: advances in structure and properties over two decades – a narrative review. Appl Sci2025; 15(3): 1108.
25.
PriyaBASenthilguruKAgarwalT, et al. Nickel doped nanohydroxyapatite: Vascular endothelial growth factor inducing biomaterial for bone tissue engineering. RSC Advances2015; 5(89): 72515–28.
26.
MunirMUSalmanSJavedI, et al. Nano-hydroxyapatite as a delivery system: overview and advancements. Artif Cells Nanomed Biotechnol2021; 49(1): 717–27.
27.
AdhikaraAGMaharaniAPPuspitasariA, et al. Bovine hydroxyapatite for bone tissue engineering: preparation, characterization, challenges, and future perspectives. Eur Polym J2024; 214: 113171.
28.
DamiriFFatimiAMusucAM, et al. Nano-hydroxyapatite (nHAp) scaffolds for bone regeneration: preparation, characterization and biological applications. J Drug Deliv Sci Technol2024; 95: 105601.
29.
NiuYChenLWuT.Recent advances in bioengineering bone revascularization based on composite materials comprising hydroxyapatite. Int J Mol Sci2023; 24(15): 12492.
FerreiraFJM. Laponite-based nanogels for bone tissue regeneration: optimization and efficacy studies. Universidade da Madeira, 2020.
32.
WangCLiuAZhaoZ, et al. Application and progress of 3D printed biomaterials in osteoporosis. Front Bioeng Biotechnol2025; 13: 1541746.
33.
RenXChenXGengZ, et al. Bone-targeted biomaterials: strategies and applications. Chem Eng J2022; 446: 137133.
34.
LiuHZhangHWangS, et al. Bone-targeted bioengineered bacterial extracellular vesicles delivering siRNA to ameliorate osteoporosis. Compos B Eng2023; 255: 110610.
35.
XinluanWYuxiaoLHelenaNH, et al. Systemic drug delivery systems for bone tissue regeneration – a mini review. Curr Pharm Des2015; 21(12): 1575–1583.
36.
MakvandiPJosicUDelfiM, et al. Drug delivery (nano) platforms for oral and dental applications: tissue regeneration, infection control, and cancer management. Adv Sci2021; 8(8): 2004014.
37.
ZhaoYXiongYZhaoY.Beyond drug delivery: metal–organic framework-derived nanosystems for bone regeneration under complicated pathological microenvironments. Acc Mater Res2024; 5(12): 1532–1543.
38.
RasouliMDarghiasiSFNaghibSM, et al. Multifunctional hydroxyapatite-based nanoparticles for biomedicine: recent progress in drug delivery and local controlled release. Curr Mech Adv Mater2021; 1(1): 3–16.
39.
El-HammadiMMAriasJL.Recent advances in the surface functionalization of PLGA-based nanomedicines. Nanomaterials2022; 12(3): 354.
40.
BrownJP.Long-term treatment of postmenopausal osteoporosis. Endocrinol Metab2021; 36(3): 544–552.
41.
MaMZengHYangP, et al. Drug delivery and therapy strategies for osteoporosis intervention. Molecules2023; 28(18): 6652.
42.
CaiRJiangYSunH, et al. Advances in functionalized nanoparticles for osteoporosis treatment. Int J Nanomedicine2025; 20: 7869–7891.
VilacaTEastellRSchiniM.Osteoporosis in men. Lancet Diabetes Endocrinol2022; 10(4): 273–283.
57.
FrancisRTuckS.Testosterone, bone and osteoporosis. Front Horm Res2009; 37: 123.
58.
KanisJAMcCloskeyEV.Risk factors in osteoporosis. Maturitas1998; 30(3): 229–233.
59.
PouresmaeiliFKamalidehghanBKamareheiM, et al. A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag2018; 14: 2029–2049.
60.
GennariC.Calcium and vitamin D nutrition and bone disease of the elderly. Public Health Nutr2001; 4(2b): 547–559.
61.
WoodRJFleetJC.The genetics of osteoporosis: vitamin D receptor polymorphisms. Annu Rev Nutr1998; 18(1): 233–258.
62.
EismanJA.Genetics, calcium intake and osteoporosis. Proc Nutr Soc1998; 57(2): 187–193.
63.
FeldsteinACNicholsGAElmerPJ, et al. Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. J Bone Joint Surg Am2003; 85(12): 2294–2302.
64.
CurrySJKristAHOwensDK, et al. Screening for osteoporosis to prevent fractures: US preventive services task force recommendation statement. JAMA2018; 319(24): 2521–2531.
65.
BlakeGMFogelmanI.The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J2007; 83(982): 509–517.
66.
SangondimathGSenRK.DEXA and imaging in osteoporosis. Indian J Orthop2023; 57(suppl 1): 82–93.
67.
El MaghraouiARouxC. DXA scanning in clinical practice. QJM2008; 101(8): 605–617.
68.
ChaddhaRAgrawalGKoiralaS, et al. Osteoporosis and vertebral column. Indian J Orthop2023; 57(suppl 1): 163–175.
69.
SinakiM. Management of fractures in osteoporosis: role of rehabilitative measures. In: Non-pharmacological management of osteoporosis: exercise, nutrition, fall and fracture prevention. Springer, 2017, pp.97–113.
70.
Al-SariUTobiasJClarkE.Health-related quality of life in older people with osteoporotic vertebral fractures: a systematic review and meta-analysis. Osteoporos Int2016; 27(10): 2891–2900.
71.
CaliriADe FilippisLBagnatoG, et al. Osteoporotic fractures: mortality and quality of life. Panminerva Med2007; 49(1): 21.
72.
JohnellO.Advances in osteoporosis: better identification of risk factors can reduce morbidity and mortality. J Intern Med1996; 239(4): 299–304.
73.
LorentzonM.Treating osteoporosis to prevent fractures: current concepts and future developments. J Intern Med2019; 285(4): 381–394.
74.
EttingerMP.Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Arch Intern Med2003; 163(18): 2237–2246.
75.
MahadikABGiriABBhambreAS, et al. Osteoporosis and lifestyle medicine. Immunodeficiency2021; 4(6): 7.
76.
ZhuKPrinceRL.Lifestyle and osteoporosis. Curr Osteoporos Rep2015; 13: 52–59.
77.
PrenticeA.Diet, nutrition and the prevention of osteoporosis. Public Health Nutr2004; 7(1a): 227–243.
78.
GruverRA.Current approaches to preventing osteoporosis: a healthy lifestyle helps protect against bone loss and includes diet, calcium supplementation, exercise, and avoidance of tobacco products and excessive alcohol consumption. Drug therapy can also be useful. JAAPA2004; 17(11): 37–42.
79.
WangL-TChenL-RChenK-H.Hormone-related and drug-induced osteoporosis: a cellular and molecular overview. Int J Mol Sci2023; 24(6): 5814.
FazilMAliABabootaS, et al. Exploring drug delivery systems for treating osteoporosis. Expert Opin Drug Deliv2013; 10(8): 1123–1136.
82.
SalamannaFGambardellaAContarteseD, et al. Nano-based biomaterials as drug delivery systems against osteoporosis: a systematic review of preclinical and clinical evidence. Nanomaterials2021; 11(2): 530.
83.
GassMDawson-HughesB.Preventing osteoporosis-related fractures: an overview. Am J Med2006; 119(4): S3–S11.
84.
TuckerKL.Osteoporosis prevention and nutrition. Curr Osteoporos Rep2009; 7(4): 111–117.
85.
DubeyMRPatelVP.Probiotics: a promising tool for calcium absorption. Open Nutr J2018; 12(1): 59–69.
86.
HarahapIASuliburskaJ.Probiotics and isoflavones as a promising therapeutic for calcium status and bone health: a narrative review. Foods2021; 10(11): 2685.
87.
Ilesanmi-OyelereBLKrugerMC.The role of milk components, pro-, pre-, and synbiotic foods in calcium absorption and bone health maintenance. Front Nutr2020; 7: 578702.
88.
Scholz-AhrensKEAdePMartenB, et al. Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure. J Nutr2007; 137(3): 838S–846S.
89.
IeloICalabreseGDe LucaG, et al. Recent advances in hydroxyapatite-based biocomposites for bone tissue regeneration in orthopedics. Int J Mol Sci2022; 23(17): 9721.
90.
PawłowskiL. Synthesis, properties and applications of hydroxyapatite. In: Industrial chemistry of oxides for emerging applications, 2018, p.311.
91.
BausoLVLa FauciVLongoC, et al. Bone tissue engineering and nanotechnology: a promising combination for bone regeneration. Biology2024; 13(4): 237.
92.
DongLDingJZhuL, et al. Copper carbonate nanoparticles as an effective biomineralized carrier to load macromolecular drugs for multimodal therapy. Chin Chem Lett2023; 34(9): 108192.
93.
Lara-OchoaSOrtega-LaraWGuerrero-BeltránCE.Hydroxyapatite nanoparticles in drug delivery: physicochemistry and applications. Pharmaceutics2021; 13(10): 1642.
94.
PaulAKBorkotokySSPrasadA.Nanohydroxyapatite-based composite materials and processing. In: PrasadAKumarAGuptaM (eds) Advanced materials and manufacturing techniques for biomedical applications, Wiley Online Library, 2023, pp.157–183.
95.
FerrazMMonteiroFManuelC.Hydroxyapatite nanoparticles: a review of preparation methodologies. J Appl Biomater Biomech2004; 2(2): 74–80.
96.
MahmutogluGTopsakalAAltanE, et al. Effects of temperature and pH on the synthesis of nanohydroxyapatite powders by chemical precipitation. J Aust Ceram Soc2023; 59(5): 1433–1441.
97.
ShoarishoarSHosseinzadehFAminiH, et al. Predication of preeclampsia severity by NLR and PLR. J Neonatal Surg2025; 14(27S): 829–836.
98.
TürkSAltınsoyİÇelebi EfeG, et al. Effect of solution and calcination time on sol-gel synthesis of hydroxyapatite. J Bionic Eng2019; 16: 311–318.
99.
ZhuQJiaoHZhaoX, et al. Hydroxyapatite formation in biomimetic synthesis with the interface of a pDA@SIS membrane. RSC Adv2022; 12(21): 13209–13219.
100.
CalisMDemirtasTTVatanseverA, et al. A biomimetic alternative to synthetic hydroxyapatite: “boron-containing bone-like hydroxyapatite” precipitated from simulated body fluid. Ann Plast Surg2017; 79(3): 304–311.
101.
ZhangXXuXZhangC, et al. Comparison of the effectiveness of teriparatide and zoledronic acid in osteoporosis treatment: a meta-analysis. Int J Pharmacol2024; 20(4): 690–697.
102.
BushraASubhaniAIslamN.A comprehensive review on biological and environmental applications of chitosan-hydroxyapatite biocomposites. Compos C Open Access2023; 12: 100402.
103.
MahantyAShikhaD.Changes in the morphology, mechanical strength and biocompatibility of polymer and metal/polymer fabricated hydroxyapatite for orthopaedic implants: a review. J Polym Eng2022; 42(4): 298–322.
104.
SaidHANoukratiHBen YoucefH, et al. Mechanical behavior of hydroxyapatite–chitosan composite: effect of processing parameters. Minerals2021; 11(2): 213.
105.
EthirajanAZienerULandfesterK.Surface-functionalized polymeric nanoparticles as templates for biomimetic mineralization of hydroxyapatite. Chem Mater2009; 21(11): 2218–2225.
106.
NabipourHBatoolSHuY.Chemical surface modification of hydroxyapatite for biomedical application: a review. Emerg Mater2023; 6(1): 31–44.
107.
MunirMUSalmanSIhsanA, et al. Synthesis, characterization, functionalization and bio-applications of hydroxyapatite nanomaterials: an overview. Int J Nanomedicine2022; 17: 1903–1925.
108.
VukomanovicMGazvodaLAnicicN, et al. Multi-doped apatite: strontium, magnesium, gallium and zinc ions synergistically affect osteogenic stimulation in human mesenchymal cells important for bone tissue engineering. Biomater Adv2022; 140: 213051.
109.
DornelasJDornelasGRossiA, et al. The incorporation of zinc into hydroxyapatite and its influence on the cellular response to biomaterials: a systematic review. J Funct Biomater2024; 15(7): 178.
110.
SinghTKaurVKumarM, et al. The critical role of bisphosphonates to target bone cancer metastasis: an overview. J Drug Target2015; 23(1): 1–15.
111.
CawthrayJWasanEWasanK.Bone-seeking agents for the treatment of bone disorders. Drug Deliv Transl Res2017; 7: 466–481.
112.
SharamiSHVojoudiEZarei-BehjaniZ, et al. From challenges to solutions: the promise of regenerative medicine and tissue engineering in restoring female reproductive health. Heliyon2025; 11(12): e43484.
113.
RoucoHGarcía-GarcíaPBriffaultE, et al. Modulating osteoclasts with nanoparticles: a path for osteoporosis management?Wiley Interdiscip Rev Nanomed Nanobiotechnol2023; 15(4): e1885.
114.
CaiYGaoTFuS, et al. Development of zoledronic acid functionalized hydroxyapatite loaded polymeric nanoparticles for the treatment of osteoporosis. Exp Ther Med2018; 16(2): 704–710.
115.
KhajuriaDKRazdanRMahapatraDR.Development, in vitro and in vivo characterization of zoledronic acid functionalized hydroxyapatite nanoparticle based formulation for treatment of osteoporosis in animal model. Eur J Pharm Sci2015; 66: 173–183.
116.
MoXZhangDLiuK, et al. Nano-hydroxyapatite composite scaffolds loaded with bioactive factors and drugs for bone tissue engineering. Int J Mol Sci2023; 24(2): 1291.
117.
BurduşelA-CGherasimOAndronescuE, et al. Inorganic nanoparticles in bone healing applications. Pharmaceutics2022; 14(4): 770.
118.
KimRY.Strategies to suppress early bone resorption induced by high dose bone morphogenetic protein-2. 서울대학교 대학원, 2016.
119.
ŁuczakJWPalusińskaMMatakD, et al. The future of bone repair: emerging technologies and biomaterials in bone regeneration. Int J Mol Sci2024; 25(23): 12766.
120.
GüldikenM.Simvastatin loaded porous hydroxyapatite based microcarriers for bone tissue engineering. Middle East Technical University, 2014.
121.
AlencastreISousaDAlvesC, et al. Delivery of pharmaceutics to bone: nanotechnologies, high-throughput processing and in silico mathematical models. Eur Cells Mater2016; 31: 355–381.
122.
ChalisserryEPNamSYAnilS.Simvastatin loaded nano hydroxyapatite in bone regeneration: a study in the rabbit femoral condyle. Curr Drug Deliv2019; 16(6): 530–537.
123.
TaoSChenS-qZhouW-t, et al. A novel biocompatible, simvastatin-loaded, bone-targeting lipid nanocarrier for treating osteoporosis more effectively. RSC Adv2020; 10(35): 20445–20459.
124.
QianGXiongLYeQ.Hydroxyapatite-based carriers for tumor targeting therapy. RSC Adv2023; 13(24): 16512–16528.
125.
WangYWangCXiaM, et al. Engineering small-molecule and protein drugs for targeting bone tumors. Mol Ther2024; 32(5): 1219–1237.
126.
ZhouHLeeJ.Nanoscale hydroxyapatite particles for bone tissue engineering. Acta Biomater2011; 7(7): 2769–2781.
127.
Asafo-AdjeiTAChenAJNajarzadehA, et al. Advances in controlled drug delivery for treatment of osteoporosis. Curr Osteoporos Rep2016; 14(5): 226–238.
128.
ZebardastALatifiTShabaniM, et al. Thrombotic storm in coronavirus disease 2019: from underlying mechanisms to its management. J Med Microbiol2022; 71(11): 001591.
129.
Mora-RaimundoPManzanoMVallet RegíM.Nanoparticles for the treatment of osteoporosis. AIMS Bioeng2017; 4(2): 259–274.
130.
StapletonMSawamotoKAlméciga-DíazCJ, et al. Development of bone targeting drugs. Int J Mol Sci2017; 18(7): 1345.
131.
JendrichovskyPKhosraviSRupasingheA, et al. Patchy harmonic functional connectivity of the mouse auditory cortex. Proc Natl Acad Sci U S A2025; 122(27): e2510012122.
132.
WarnerAJHathaway-SchraderJDLubkerR, et al. Tetracyclines and bone: unclear actions with potentially lasting effects. Bone2022; 159: 116377.
133.
WangHLiuJTaoS, et al. Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system. Int J Nanomedicine2015; 10: 5671–5685.
134.
HsuY-WMaLTangY, et al. The application of aptamers in the repair of bone, nerve, and vascular tissues. J Mater Chem B2025; 13(6): 1872–1889.
135.
LiuMKinghornABWangL, et al. The evolution and application of a novel DNA aptamer targeting bone morphogenetic protein 2 for bone regeneration. Molecules2024; 29(6): 1243.
136.
HuangYChenMShenY, et al. Bone-targeting cell membrane-engineered CaCO3-based nanoparticles restore local bone homeostasis for microenvironment-responsive osteoporosis treatment. Chem Eng J2023; 470: 144145.
137.
YangDHNahHLeeD, et al. A review on gold nanoparticles as an innovative therapeutic cue in bone tissue engineering: prospects and future clinical applications. Mater Today Bio2024; 26: 101016.
138.
LiHPanSXiaP, et al. Advances in the application of gold nanoparticles in bone tissue engineering. J Biol Eng2020; 14: 1–15.
139.
KamaliMJSaeediFKhoshghiafehA, et al. Therapeutic targeting of triple-negative breast cancer: a multi-model evaluation of LNA-anti-miR-19b-3p and small molecule inhibitors. Comput Biol Med2025; 196: 110771.
140.
OroojalianFBeygiMBaradaranB, et al. Immune cell membrane-coated biomimetic nanoparticles for targeted cancer therapy. Small2021; 17(12): 2006484.
141.
LiMYuBWangS, et al. Microenvironment-responsive nanocarriers for targeted bone disease therapy. Nano Today2023; 50: 101838.
142.
WeiHCuiJLinK, et al. Recent advances in smart stimuli-responsive biomaterials for bone therapeutics and regeneration. Bone Res2022; 10(1): 17.
143.
BakirMDawalibiAMuftiMA, et al. Nano-drug delivery systems for bone metastases: targeting the tumor–bone microenvironment. Pharmaceutics2025; 17(5): 603.
144.
LuhmannTGermershausOGrollJ, et al. Bone targeting for the treatment of osteoporosis. J Control Release2012; 161(2): 198–213.
145.
MuraSNicolasJCouvreurP.Stimuli-responsive nanocarriers for drug delivery. Nat Mater2013; 12(11): 991–1003.
146.
MajumderJMinkoT.Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv2021; 18(2): 205–227.
147.
WoodSLBrownJE.Personal medicine and bone metastases: biomarkers, micro-RNAs and bone metastases. Cancers2020; 12(8): 2109.
148.
DhoundiyalSSrivastavaSKumarS, et al. Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. Eur J Med Res2024; 29(1): 26.
149.
VinayRKusumDeviV.Potential of targeted drug delivery system for the treatment of bone metastasis. Drug Deliv2016; 23(1): 21–29.
150.
De Lama-OdríaMDCDel ValleLJPuiggalíJ.Hydroxyapatite biobased materials for treatment and diagnosis of cancer. Int J Mol Sci2022; 23(19): 11352.
151.
SantoVEGomesMEManoJF, et al. From nano-to macro-scale: nanotechnology approaches for spatially controlled delivery of bioactive factors for bone and cartilage engineering. Nanomedicine2012; 7(7): 1045–1066.
152.
SyamchandSSSonyG.Multifunctional hydroxyapatite nanoparticles for drug delivery and multimodal molecular imaging. Microchim Acta2015; 182: 1567–1589.
153.
MysoreTHMPatilAYHegdeC, et al. Apatite insights: from synthesis to biomedical applications. Eur Polym J2024; 209: 112842.
154.
LiuXMiaoYLiangH, et al. 3D-printed bioactive ceramic scaffolds with biomimetic micro/nano-HAp surfaces mediated cell fate and promoted bone augmentation of the bone–implant interface in vivo. Bioact Mater2022; 12: 120–132.
155.
GeorgeSMNayakCSinghI, et al. Multifunctional hydroxyapatite composites for orthopedic applications: a review. ACS Biomater Sci Eng2022; 8(8): 3162–3186.
156.
PrzekoraAGinalskaG.Enhanced differentiation of osteoblastic cells on novel chitosan/β-1, 3-glucan/bioceramic scaffolds for bone tissue regeneration. Biomed Mater2015; 10(1): 015009.
157.
TranTHHLuuCHNguyenKTT, et al. Mineralized biopolymers-based scaffold encapsulating with dual drugs for alveolar ridge preservation. Macromol Biosci2025; 25(2): 2400351.
158.
ZebardastAPazhoohanMCheratiAY, et al. Higher viral load of Epstein–Barr virus in gastric cancer compared with non-cancerous gastroduodenal tissues. Infez Med2022; 30(2): 263.
159.
ChengXWeiJGeQ, et al. The optimized drug delivery systems of treating cancer bone metastatic osteolysis with nanomaterials. Drug Deliv2021; 28(1): 37–53.
160.
NielsenJJLowSA.Bone-targeting systems to systemically deliver therapeutics to bone fractures for accelerated healing. Curr Osteoporos Rep2020; 18(5): 449–459.
161.
MondalSDorozhkinSVPalU.Recent progress on fabrication and drug delivery applications of nanostructured hydroxyapatite. Wiley Interdiscip Rev Nanomed Nanobiotechnol2018; 10(4): e1504.
162.
TangSShenYJiangL, et al. Surface modification of nano-hydroxyapatite/polymer composite for bone tissue repair applications: a review. Polymers2024; 16(9): 1263.
163.
OnziGGuterresSSPohlmannAR, et al. Passive targeting and the enhanced permeability and retention (EPR) effect. In: The ADME encyclopedia: a comprehensive guide on biopharmacy and pharmacokinetics, 2021, pp.1–13.
164.
ShindeVRReviNMurugappanS, et al. Enhanced permeability and retention effect: a key facilitator for solid tumor targeting by nanoparticles. Photodiagnosis Photodyn Ther2022; 39: 102915.
165.
EbrahimiMRadMTSZebardastA, et al. The critical role of mesenchymal stromal/stem cell therapy in COVID-19 patients: an updated review. Cell Biochem Funct2021; 39(8): 945–954.
166.
ZhouXCornelEJHeS, et al. Recent advances in bone-targeting nanoparticles for biomedical applications. Mater Chem Front2021; 5(18): 6735–6759.
167.
ColeLEVargo-GogolaTRoederRK.Targeted delivery to bone and mineral deposits using bisphosphonate ligands. Adv Drug Deliv Rev2016; 99: 12–27.
168.
OssipovDA.Bisphosphonate-modified biomaterials for drug delivery and bone tissue engineering. Expert Opinion Drug Deliv2015; 12(9): 1443–1458.
169.
GeraSSampathiSDodoalaS.Role of nanoparticles in drug delivery and regenerative therapy for bone diseases. Curr Drug Deliv2017; 14(7): 904–916.
170.
Jiménez-PérezAMartínez-AlonsoMGarcía-TojalJ.Hybrid hydroxyapatite–metal complex materials derived from amino acids and nucleobases. Molecules2024; 29(18): 4479.
171.
BoaniniETorricelliPGazzanoM, et al. Nanocomposites of hydroxyapatite with aspartic acid and glutamic acid and their interaction with osteoblast-like cells. Biomaterials2006; 27(25): 4428–4433.
172.
TanXXueZZhuH, et al. How charged amino acids regulate nucleation of biomimetic hydroxyapatite nanoparticles on the surface of collagen mimetic peptides: molecular dynamics and free energy investigations. Cryst Growth Des2020; 20(7): 4561–4572.
173.
WangYWangCXiaM, et al. Engineering small-molecule and protein drugs for targeting bone tumors. Mol Ther2024; 32(5): 1219–1237.
174.
WangYWenJLuT, et al. Mesenchymal stem cell-derived extracellular vesicles in bone-related diseases: intercellular communication messengers and therapeutic engineering protagonists. Int J Nanomedicine2024; 19: 3233–3257.
175.
MaryAReddySGKumarBS, et al. Novel approaches to alendronate delivery beyond oral administration – a review. Eng Sci2024; 32: 1274.
176.
KlaraJLewandowska-ŁańcuckaJ.How efficient are alendronate-nano/biomaterial combinations for anti-osteoporosis therapy? An evidence-based review of the literature. Int J Nanomedicine2022; 17: 6065.
177.
GalindoTGPChaiYTagayaM. Hydroxyapatite nanoparticle coating on polymer for constructing effective biointeractive interfaces. J Nanomater2019; 2019(1): 6495239.
178.
GhiasiBSefidbakhtYMozaffari-JovinS, et al. Hydroxyapatite as a biomaterial – a gift that keeps on giving. Drug Dev Ind Pharm2020; 46(7): 1035–1062.
179.
HoqueJShihY-RVZengY, et al. Bone targeting nanocarrier-assisted delivery of adenosine to combat osteoporotic bone loss. Biomaterials2021; 273: 120819.
180.
WangC-ZEswaramoorthyRLinT-H, et al. Enhancement of chondrogenesis of adipose-derived stem cells in HA-PNIPAAm-CL hydrogel for cartilage regeneration in rabbits. Sci Rep2018; 8(1): 10526.
181.
SprioSPretiLMontesiM, et al. Surface phenomena enhancing the antibacterial and osteogenic ability of nanocrystalline hydroxyapatite, activated by multiple-ion doping. ACS Biomater Sci Eng2019; 5(11): 5947–5959.
182.
SinghGSinghRPJollySS.Customized hydroxyapatites for bone-tissue engineering and drug delivery applications: a review. J Sol-Gel Sci Technol2020; 94: 505–530.
183.
RamadanAAMotaweaITEltayebHE.Bioactivity and antibacterial effect of zinc doped hydroxyapatite as bone scaffold. Al-Azhar J Dent2024; 12(1): 3.
184.
SoltaniSFarahaniAZebardastA, et al. Human immunodeficiency virus and Candida albicans co-infection in Iran: a systematic review. HIV AIDS Rev2023; 22(3): 181–188.
185.
El-HusseinyHMMadyEAEl-DakrouryWA, et al. Smart/stimuli-responsive hydrogels: state-of-the-art platforms for bone tissue engineering. Appl Mater Today2022; 29: 101560.
186.
MazidiZJavanmardiSNaghibSM, et al. Smart stimuli-responsive implantable drug delivery systems for programmed and on-demand cancer treatment: an overview on the emerging materials. Chem Eng J2022; 433: 134569.
187.
QuMJiangXZhouX, et al. Stimuli-responsive delivery of growth factors for tissue engineering. Adv Healthc Mater2020; 9(7): 1901714.
188.
QiaoYWanJZhouL, et al. Stimuli-responsive nanotherapeutics for precision drug delivery and cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol2019; 11(1): e1527.
189.
DingCTongLFengJ, et al. Recent advances in stimuli-responsive release function drug delivery systems for tumor treatment. Molecules2016; 21(12): 1715.
190.
LiLYangW-WXuD-G.Stimuli-responsive nanoscale drug delivery systems for cancer therapy. J Drug Target2019; 27(4): 423–433.
191.
ZhangQQiangLLiuY, et al. Biomaterial-assisted tumor therapy: A brief review of hydroxyapatite nanoparticles and its composites used in bone tumors therapy. Front Bioeng Biotechnol2023; 11: 1167474.
192.
ThurnerGCHaybaeckJDebbageP.Targeting drug delivery in the elderly: are nanoparticles an option for treating osteoporosis?Int J Mol Sci2021; 22(16): 8932.
193.
YangXChenSLiuX, et al. Drug delivery based on nanotechnology for target bone disease. Curr Drug Deliv2019; 16(9): 782–792.
194.
UskokovićVJanković-ČastvanIWuVM.Bone mineral crystallinity governs the orchestration of ossification and resorption during bone remodeling. ACS Biomater Sci Eng2019; 5(7): 3483–3498.
195.
LiSLinYMoC, et al. Application of metal–organic framework materials in regenerative medicine. J Mater Chem B2024; 12(35): 8543–8576.
196.
WenWGuoPXueHY, et al. Development of local injectable, bone-targeting nanocarriers of triptolide for treatment of bone-only metastasis. Int J Pharm2022; 625: 122092.
197.
GeusensPBeversMSvan RietbergenB, et al. Effect of denosumab compared with risedronate on bone strength in patients initiating or continuing glucocorticoid treatment. J Bone Miner Res2020; 37(6): 1136–1146.
198.
TangSAllenMRPhippsR, et al. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int2009; 20: 887–894.
199.
WenJCaiDGaoW, et al. Osteoimmunomodulatory nanoparticles for bone regeneration. Nanomaterials2023; 13(4): 692.
200.
ChenJZhaoYRuanR, et al. Bone morphogenetic protein-2-derived peptide-conjugated nanozyme-integrated photoenhanced hybrid hydrogel for cascade-regulated bone regeneration. ACS Nano2025; 19(15): 14707–14726.
201.
BaigMSAhmadAPathanRR, et al. Precision nanomedicine with bio-inspired nanosystems: recent trends and challenges in mesenchymal stem cells membrane-coated bioengineered nanocarriers in targeted nanotherapeutics. J Xenobiot2024; 14(3): 827–872.
202.
LiYWangYZhaoH, et al. Engineering strategies of plant-derived exosome-like nanovesicles: current knowledge and future perspectives. Int J Nanomedicine2024; 19: 12793–12815.
203.
GhaffariMMoztarzadehFMollazadeh-BajestaniS. Drug delivery nanosystems for musculoskeletal regeneration. In: Nanoengineering in musculoskeletal regeneration. Elsevier, 2020, pp.77–103.
204.
GovindanBSwarna LathaBNagamonyP, et al. Designed synthesis of nanostructured magnetic hydroxyapatite based drug nanocarrier for anti-cancer drug delivery toward the treatment of human epidermoid carcinoma. Nanomaterials2017; 7(6): 138.
205.
GuoWLiYWangS, et al. Photodynamic nano hydroxyapatite with biofilm penetration capability for dental plaque eradication and prevention of demineralization. Colloids Surf B Biointerfaces2023; 225: 113242.
206.
ZhangHFanTChenW, et al. Recent advances of two-dimensional materials in smart drug delivery nano-systems. Bioact Mater2020; 5(4): 1071–1086.
207.
HaroonBSohailMMinhasMU, et al. Nano-residronate loaded κ-carrageenan-based injectable hydrogels for bone tissue regeneration. Int J Biol Macromol2023; 251: 126380.
208.
HuJDingYTaoB, et al. Surface modification of titanium substrate via combining photothermal therapy and quorum-sensing-inhibition strategy for improving osseointegration and treating biofilm-associated bacterial infection. Bioact Mater2022; 18: 228–241.
209.
SaeediFSalehiMKamaliMJ, et al. Evaluation of the cytotoxic activities of the essential oil from Pistacia atlantica Desf. oleoresin on human gastric cancer cell lines. Med Oncol2024; 41(6): 1–9.
210.
IonescuABrambillaE.New generation restorative dental biomaterials that modulate biofilm formation. In: Biomaterials and novel technologies for healthcare. CNR Edizioni, 2018, pp.149–150.
211.
PanzavoltaSTorricelliPBracciB, et al. Functionalization of biomimetic calcium phosphate bone cements with alendronate. J Inorg Biochem2010; 104(10): 1099–1106.
212.
RawatPAhmadIThomasSC, et al. Revisiting bone targeting potential of novel hydroxyapatite based surface modified PLGA nanoparticles of risedronate: pharmacokinetic and biochemical assessment. Int J Pharm2016; 506(1): 253–261.
213.
MaryczKSmieszekAMarcinkowskaK, et al. Nanohydroxyapatite (nHAp) doped with iron oxide nanoparticles (IO), miR-21 and miR-124 under magnetic field conditions modulates osteoblast viability, reduces inflammation and inhibits the growth of osteoclast – a novel concept for osteoporosis treatment: part 1. Int J Nanomedicine2021; 16: 3429–3456.
214.
KotakDJDevarajanPV.Bone targeted delivery of salmon calcitonin hydroxyapatite nanoparticles for sublingual osteoporosis therapy (SLOT). Nanomedicine2020; 24: 102153.
215.
KhajuriaDKDishaCVasireddiR, et al. Risedronate/zinc-hydroxyapatite based nanomedicine for osteoporosis. Mater Sci Eng C Mater Biol Appl2016; 63: 78–87.
216.
ZhaoRShangTYuanB, et al. Osteoporotic bone recovery by a bamboo-structured bioceramic with controlled release of hydroxyapatite nanoparticles. Bioact Mater2022; 17: 379–393.
217.
HwangS-JLeeJ-SRyuT-K, et al. Alendronate-modified hydroxyapatite nanoparticles for bone-specific dual delivery of drug and bone mineral. Macromol Res2016; 24: 623–628.
218.
ChenMLinYWangH, et al. Function of calcium-rich hydroxyapatite nanoparticles on proliferation and differentiation of bone marrow mesenchymal stem cells (BMSCs) in osteoporosis. Mater Express2022; 12(2): 214–219.
219.
LanJSZengRFLiZ, et al. CD44-targeted photoactivatable polymeric nanosystem with on-demand drug release as a “photoactivatable bomb” for combined photodynamic therapy–chemotherapy of cancer. ACS Appl Mater Interfaces2023; 15(29): 34554–34569.
220.
LiMSunJZhangW, et al. Drug delivery systems based on CD44-targeted glycosaminoglycans for cancer therapy. Carbohydr Polym2021; 251: 117103.
221.
LimaACFerreiraHReisRL, et al. Biodegradable polymers: an update on drug delivery in bone and cartilage diseases. Expert Opin Drug Deliv2019; 16(8): 795–813.
222.
LimitiEMozeticPGiannitelliSM, et al. Hyaluronic acid–polyethyleneimine nanogels for controlled drug delivery in cancer treatment. ACS Appl Nano Mater2022; 5(4): 5544–5557.
223.
LiuY. Hydroxyapatite-A trojan horse in the delivery of apatite-binding cytostatics in bone cancer. Lund University, 2022, p. 117.
224.
WangYXuYSongJ, et al. Tumor cell-targeting and tumor microenvironment-responsive nanoplatforms for the multimodal imaging-guided photodynamic/photothermal/chemodynamic treatment of cervical cancer. Int J Nanomedicine2024; 19: 5837–5858.
225.
LiuYSunJZhangP, et al. Amphiphilic polysaccharide-hydrophobicized graft polymeric micelles for drug delivery nanosystems. Curr Med Chem2011; 18(17): 2638–2648.
226.
WangXXuanZZhuX, et al. Near-infrared photoresponsive drug delivery nanosystems for cancer photo-chemotherapy. J Nanobiotechnol2020; 18(1): 108.
227.
WangXZhongXLiJ, et al. Inorganic nanomaterials with rapid clearance for biomedical applications. Chem Soc Rev2021; 50(15): 8669–8742.
228.
WeiYDengYMaS, et al. Local drug delivery systems as therapeutic strategies against periodontitis: a systematic review. J Control Release2021; 333: 269–282.
229.
WilsonCJCleggRELeavesleyDI, et al. Mediation of biomaterial–cell interactions by adsorbed proteins: a review. Tissue Eng2005; 11(1–2): 1–18.
230.
WuCChangJ.Mesoporous bioactive glasses: structure characteristics, drug/growth factor delivery and bone regeneration application. Interface Focus2012; 2(3): 292–306.
231.
XiangZLiuMSongJ.Stimuli-responsive polymeric nanosystems for controlled drug delivery. Appl Sci2021; 11(20): 9541.
232.
DuJMengXYangM, et al. NGR-modified CAF-derived exos targeting tumor vasculature to induce ferroptosis and overcome chemoresistance in osteosarcoma. Adv Sci2025; 12(12): 2410918.
233.
YangBMengFZhangJ, et al. Engineered drug delivery nanosystems for tumor microenvironment normalization therapy. Nano Today2023; 49: 101766.
234.
ZakariaSMSharif ZeinSHOthmanMR, et al. Nanophase hydroxyapatite as a biomaterial in advanced hard tissue engineering: a review. Tissue Eng B Rev2013; 19(5): 431–441.
235.
LuoJCuiYXuL, et al. Layered double hydroxides for regenerative nanomedicine and tissue engineering: recent advances and future perspectives. J Nanobiotechnol2025; 23(1): 370.
236.
MoghadamNBAvatefiMKarimiM, et al. Graphene family in cancer therapy: recent progress in cancer gene/drug delivery applications. J Mater Chem B2023; 11(12): 2568–2613.
237.
MardirossianMGruppusoMGuagniniB, et al. Advantages of agarose on alginate for the preparation of polysaccharide/hydroxyapatite porous bone scaffolds compatible with a proline-rich antimicrobial peptide. Biomed Mater2023; 18(6): 065018.
238.
MashakABazraeeSMobediH.Advances in drug delivery and biomedical applications of hydroxyapatite-based systems: a review. Bull Mater Sci2022; 45(4): 183.
239.
GuoXLiJWuY, et al. Recent advancements in hydrogels as novel tissue engineering scaffolds for dental pulp regeneration. Int J Biol Macromol2024; 264: 130708.
240.
MondalDWillettTL.Three-dimensional printable nanocomposite biomaterials as bone scaffolds and grafts. In: Smart multifunctional nano-inks. Elsevier, 2023, pp.579–594.
PaulWSharmaCP. Inorganic nanoparticles for targeted drug delivery. Biointegration of medical implant materials. 2020; 1: 333–373.
243.
SobierajskaPPozniakBTikhomirovM, et al. Multifunctionality of nanosized calcium apatite dual-doped with Li+/Eu3+ ions related to cell culture studies and cytotoxicity evaluation in vitro. Biomolecules2021; 11(9): 1388.
244.
SunFZhangPLiuY, et al. A photo-controlled hyaluronan-based drug delivery nanosystem for cancer therapy. Carbohydr Polym2019; 206: 309–318.
245.
SunL.Self-assembled Rosette nanotubes for tissue engineering and drug delivery applications. Northeastern University, 2014.
246.
TalibWHAlsalahatIDaoudS, et al. Plant-derived natural products in cancer research: extraction, mechanism of action, and drug formulation. Molecules2020; 25(22): 5319.
247.
TanLLiMLuoZ, et al. Black phosphorus biomaterials for photo-controlled bone tissue engineering. Compos B Eng. Elsevier2022; 246: 110245.
248.
NarayananDAnithaAJayakumarR, et al. In vitro and in vivo evaluation of osteoporosis therapeutic peptide PTH 1–34 loaded PEGylated chitosan nanoparticles. Mol Pharm2013; 10(11): 4159–4167.
249.
TangWYuanYLiuC, et al. Differential cytotoxicity and particle action of hydroxyapatite nanoparticles in human cancer cells. Nanomedicine2014; 9(3): 397–412.
250.
VeigaAMadureiraSCostaJB, et al. Tackling current production of HAp and HAp-driven biomaterials. Mater Adv2023; 4(22): 5453–5478.
251.
WanWLiZWangX, et al. Surface-fabrication of fluorescent hydroxyapatite for cancer cell imaging and bio-printing applications. Biosensors2022; 12(6): 419.
252.
WanWLiZWangX, et al. Rapid preparation of hyperbranched β-CD functionalized hydroxyapatite based on host–guest reaction for cell imaging and drug delivery. Colloids Surf A Physicochem Eng Asp2022; 654: 130099.
253.
AnilSSureshNSweetyVK, et al. Biocompatible nanocomposites: an overview of materials used in biomedical applications. In: Biocompatible nanocomposites: from synthesis to applications, Springer, 2025, pp.17–61.
254.
RadicMMBVukomanovicMNikodinovic-RunicJ, et al. 28.1 Graphene oxide-based materials for biomedical applications. Theranos Nanosyst2023; 3: 763.
255.
CarellaFDegli EspostiLAdamianoA, et al. The use of calcium phosphates in cosmetics, state of the art and future perspectives. Materials2021; 14(21): 6398.
256.
OrdikhaniFZandiNMazaheriM, et al. Targeted nanomedicines for the treatment of bone disease and regeneration. Med Res Rev2021; 41(3): 1221–1254.
257.
WangYNewmanMRAckun-FarmmerM, et al. Fracture-targeted delivery of β-catenin agonists via peptide-functionalized nanoparticles augments fracture healing. ACS Nano2017; 11(9): 9445–9458.
258.
HuangTQiaoSWangJ, et al. The journey of functional nanoparticles in the human hard tissue mineralization: classification, key functions, and future perspectives. Small2025; 21(37): e04003.
259.
MishraDHubenakJRMathurAB.Nanoparticle systems as tools to improve drug delivery and therapeutic efficacy. J Biomed Mater Res A2013; 101(12): 3646–3660.
260.
MitchellMJBillingsleyMMHaleyRM, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov2021; 20(2): 101–124.
261.
ChenthamaraDSubramaniamSRamakrishnanSG, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res2019; 23(1): 20.
262.
NatarajanJVNugrahaCNgXW, et al. Sustained-release from nanocarriers: a review. J Control Release2014; 193: 122–138.
263.
WeiYQuanLZhouC, et al. Factors relating to the biodistribution & clearance of nanoparticles & their effects on in vivo application. Nanomedicine2018; 13(12): 1495–1512.
264.
SunTZhangYSPangB, et al. Engineered nanoparticles for drug delivery in cancer therapy. In: Nanomaterials and neoplasms, 2021, pp.31–142.
265.
KamalyNYameenBWuJ, et al. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev2016; 116(4): 2602–2663.
266.
FangCKievitFMVeisehO, et al. Fabrication of magnetic nanoparticles with controllable drug loading and release through a simple assembly approach. J Control Release2012; 162(1): 233–241.
267.
ZaibudeenA.Recent advances in different nanoprecipitation methods for efficient drug loading and controlled release. J Nanotechnol Nanomater2025; 6(1): 12–25.
268.
TranVNguyenNRenkesS, et al. Current and near-future technologies to quantify nanoparticle therapeutic loading efficiency and surface coating efficiency with targeted moieties. Bioengineering2025; 12(4): 362.
269.
Shetab BoushehriMALamprechtA. Nanoparticles as drug carriers: current issues with in vitro testing. Nanomedicine2015; 10(21): 3213–3230.
270.
LousaIR.Pharmaceutical regulation of nanomedicines: principles and challenges. Universidade de Lisboa, 2024.
271.
KhopadeAJShahM. Challenges for commercial translation of nanomedicines: from lab scale to production scale. In: Commercial scale production of nanomedicines. CRC Press, 2025, pp.1–40.
272.
de Souza Cardoso DelfinoCde Paula PereiraMCdos Santos OliveiraM, et al. Scaling nanopharmaceutical production for personalized medicine: challenges and strategies. J Nanopart Res2025; 27(4): 1–19.
273.
KardaniSL.Nanocarrier-based formulations: regulatory challenges, ethical and safety considerations in pharmaceuticals. Asian J Pharm2024; 18(2): 5444.
274.
ĐorđevićSGonzalezMMConejos-SánchezI, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res2022; 12(3): 500–525.
275.
PistoneAIannazzoDPanseriS, et al. Hydroxyapatite–magnetite–MWCNT nanocomposite as a biocompatible multifunctional drug delivery system for bone tissue engineering. Nanotechnology2014; 25(42): 425701.
276.
PrasherPSharmaMMehtaM, et al. Current-status and applications of polysaccharides in drug delivery systems. Colloid Interface Sci Commun2021; 42: 100418.
277.
PreethiABellareJR. Tailoring scaffolds for orthopedic application with anti-microbial properties: current scenario and future prospects. Front Mater2021; 7: 594686.
278.
CañasMR.Hydroxyapatite-based materials for smart antitumor drug delivery systems, endocytic pathways and endosomal trafficking: polymers and biopolymers. Universitat Politècnica de Catalunya, 2020.
279.
SachinKKarnSK.Microbial fabricated nanosystems: applications in drug delivery and targeting. Front Chem2021; 9: 617353.
280.
SengarPChauhanKHirataGA.Progress on carbon dots and hydroxyapatite based biocompatible luminescent nanomaterials for cancer theranostics. Transl Oncol2022; 24: 101482.
281.
ShangLShaoJGeS.Immunomodulatory properties: the accelerant of hydroxyapatite-based materials for bone regeneration. Tissue Eng C Methods2022; 28(8): 377–392.
282.
NeacsuIAStoicaAEVasileBS, et al. Luminescent hydroxyapatite doped with rare earth elements for biomedical applications. Nanomaterials2019; 9(2): 239.
283.
SinghDDubeyPPradhanM, et al. Ceramic nanocarriers: versatile nanosystem for protein and peptide delivery. Expert Opin Drug Deliv2013; 10(2): 241–259.
